Dexcom reported preliminary, unaudited total revenue of $1.260 billion for the fourth quarter of 2025, an increase of 13% over the fourth quarter of 2024.

DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...

Continuous glucose monitoring is associated with lower all-cause mortality in older adults with diabetes and ADRD compared with self-monitoring.

While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company ...

In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...

Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

Wearable makers like Apple, Samsung, Garmin, Google have long chased what might be the holy grail of health tech: ...